Ladies and gentlemen, thank you for standing by, and welcome to the Q1 MediWound 2020 Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today, Jeremy Feffer. Thank you. Please go ahead, sir.

Thank you, Brandy and good morning, everyone. Earlier today, MediWound issued a press release announcing financial results and provided a business update for the first quarter of 2020. You may access that release on the company's website under the Investors tab. With us today are Sharon Malka, Chief Executive Officer of MediWound; and Boaz Gur-Lavie, Chief Financial Officer. Following management's prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWound's expected future performance, future business prospects or future events or plans, are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although, the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from the forecast due to the impact of many factors beyond the control of MediWound. The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to cautionary notes set forth in today's press release, as well as the risk factors set forth in MediWound's Annual Report 2019, as well as information contained in other documents filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. This conference call is the property of MediWound and any recording or rebroadcast is expressly prohibited without the written consent of MediWound. At this time, I would like to turn the call over to Sharon Malka, Chief Executive Officer. Sharon?

Thank you, Jeremy. Good morning everyone and good afternoon to our listeners in Israel. Thank you everyone for joining us today on our first quarter 2020 earning call, which will provide business and financial updates related to the COVID-19 pandemic. First, we are thankful to the healthcare workers for the critical efforts in the treatment and care of COVID-19 patients and our thoughts go out to those affected by the COVID-19 pandemic. We would also like to thank all of our employees for the tremendous dedication, commitment and flexibility demonstrated during this crisis enabling us to carry on critical business function. We entered 2020 with great momentum after an extremely productive 2019, looking forward to another exciting year. This quarter has been unique and with the impact of the COVID-19 pandemic, unlike anything we could have anticipated when the year began. Let me walk through and review what took place during the quarter for us. Over the past several weeks, we have implemented a number of measures in response to the COVID-19 pandemic to ensure continuous manufacturing and supply of NexoBrid to healthcare providers and patients with severe burn injuries. Reinstituted a global remote work policy with our employees who could work-from-home, while we implemented a modified work schedule for all the operational personnel walking at our facility to ensure their safety. We leverage virtual tools and digital communication to continue our interactions with all of our stakeholders and to support physicians in the region where executive order or hospital policies restricted access. As Boaz will cover in more detail in a moment, we also implemented appropriate expense reduction measures and adjusted our operating plan for 2020. While many of the COVID-19 related restrictions are still in place globally, we are now beginning to see the lifting or soon to…

Thank you, Sharon and good morning, everyone. I would like to start with the financial overview of our response to the COVID-19 crisis. We have adjusted our 2020 operating plan and implemented prudent measures to reduce operating expenses and deferring non-essential capital projects in order to reduce the company's cash utilization, while maintaining flexibility for additional expense reduction in the future, if necessary. As a result of the EscharEx study patients' enrollment suspension, variable costs associated with a clinical trial will lead to cost saving in the short-term. Additionally, with the overall SG&A costs would be reduced on an annual basis. I would like now to provide you with an update on our financial performance for the first quarter of 2020. Revenues for the first quarter of 2020 were $4.4 million versus $0.5 million in the first quarter of 2019, primarily driven by revenues from development services. Gross profit for the first quarter of 2020 was $1.2 million compared with $0.2 million in the prior period. R&D expenses, net of participation for the quarter, were $1.7 million compared with the $1.3 million for the first quarter of 2019, primarily driven by EscharEx development costs. SG&A expenses for the quarter were $1.7 million compared with $2.4 million for the first quarter of 2019, primarily as a result of cost containment measures and one-time costs in the first quarter of 2019 associated with management changes. Operating loss for the quarter was $2.2 million, a reduction of 38% compared with the loss of $3.6 million in the first quarter of 2019. The company's net loss for the quarter was $2.5 million or a loss of $0.09 per share compared with a net loss of $4.1 million or loss of $0.15 per share for the first quarter of 2019. Adjusted EBITDA for the quarter was a loss of $1.8 million compared with the loss of $2.9 million in the first quarter of 2019. The reconciliation of adjusted EBITDA to GAAP net income is included in the press release we filed with the SEC earlier this morning. Operating cash flow for the quarter was $2.1 million and as of March 31, 2020 the company had cash and short-term bank deposits of $27.3 million and carried no debt. The company will continue to invest primarily in research and development efforts for EscharEx and reiterating our expectation of cash use for operating activities in 2020 to be in the range of $8 million to $10 million. While at this time the company cannot predict the extent or duration of the impact of the COVID-19 outbreak on its ongoing financial and operational results, we will continue to closely monitor our preparation and assess the impact of the COVID-19. With that, I have concluded the financial overview. I will now turn the call back over to Sharon. Sharon?

Thanks, Boaz. Despite the uncertainty caused by the COVID-19 crisis, we remain highly confident in the fundamentals of our business. We appreciate the support of our Board and we are also grateful for the tremendous effort and commitment of our management and employees as we face these pandemic together. We are fortunate to have a strong balance sheet to help us weather the storm. EscharEx trial is once again underway at most clinics, and we eagerly anticipate our NexoBrid BLA filing soon. Our confidence in our strategy and our programs has not wavered. We will continue executing our plans and actively progressing towards several meaningful milestones in both programs. That concludes our prepared remarks. Now, I'd like to operator to open the call for your questions. Operator?

[Operator Instructions] Your first question comes from the line of Josh Jennings with Cowen.

Hi. Good morning, Sharon and Boaz. Thanks for the update. I was hoping to start on a couple of questions on NexoBrid. First -- and it was great to hear that the BLA filing timing is unchanged. Maybe you could just help us think about what steps are left in the submission process and what are the risks of hitting that timeline as midyear 2020 is in the coming weeks, two months.

Thanks Josh for the question. We are pleased with our BLA progress and the collaboration we have with both Vericel team and BARDA team. And as I said before, despite the COVID-19 disruptions, we remain on track with the preparation and submission, and believe that we will submit the BLA no later than early July. We are currently at the final stage of QA of the different models, publishing and we are there.

Excellent. No, thanks for that extra color. And if we think we think about the BARDA procurements, I think you are talking about the third quarter where procurement will kick back in or kick-in. I believe Vericel in their earnings call talked about assuming nothing until 2021. And just wanted to sanity check if that was their messaging? And what is the difference between your timeline today? Has there been an update in the interim or -- just wanted to check in on that. And then also on the same -- in the same vein, we've just historically assumed kind of a straight line of BARDA procurement from a revenue modeling perspective over a six-quarter timeframe. And then should we be continuing to think about that type of modeling in terms of BARDA procurement steady flow quarter after quarter.

Thanks for the question. So, to put us all on the same page with our expectation, I will start with our previous announcement which indeed specified the first delivery by end of the first quarter of 2020. While we have also indicated that the revenue recognition is likely to occur starting from second quarter due to BARDA acceptance processes. Following the initiation of the procurement of NexoBrid for emergency response, earlier this year, we at MediWound began manufacturing of NexoBrid and building an emergency stockpile ready for delivery, which is currently we maintain it in Israel. BARDA requested an adjustment due to the COVID-19 and shifting priorities to the delivery plan of NexoBrid emergency stockpile. While the definitive delivery plan is not yet schedule based on recent discussion we have with -- we had with BARDA, the first delivery is currently expected in the third quarter of 2020, followed by subsequent deliveries in the following quarters. So, we do expect revenues from BARDA procurement in the second half of 2020, while the majority of the deliveries will occur in 2021. And the linear split, as we said before, this is quarterly revenue recognition starting from the third quarter going forward.

Excellent. If I could just shift over to EscharEx and thinking about the interim analysis timeline in mid-2021. Are you still targeting a 100 patients for that interim analysis? And when -- how should we be thinking about the overall trial enrollment completion timeline? Should we be thinking about that sometime in 2022?

So, the short answer for the first part of the question is, yes. The targeting number of patients to be treated to all the interim assessment is around the 100, as defined in the protocol. What I can share with you is that we are very pleased that we were able to resume the study in regions where restrictions have been lifted, and we now can screen and randomize patients. As you may recall, the first quarter of 2020 was the setup period of this study, focusing on sites opening and staff training. Patients who already enrolled before we suspend the study, during the setup period continued the treatment in accordance with the study protocol and were monitored using remote site monitoring tools, and none of these patients have been lost to follow-up due to the COVID-19. In light of the fact that several states have recently announced plans to lift restrictions, we are monitoring side by side and stand ready to swiftly resume enrollment at all sites as soon as it is practical. And I believe that we need more time to evaluate the pace of recruitment, which is subject to three main factors. One is, of course, the governmental policies, which is evolving. And hopefully in the coming months, we'll see more and more lifting of the suspicions. Two, the readiness and ability of individual facilities to resume clinical trials, because it's side by side policy. And the third one, which is not less important, is the willingness and ability of patients to return to clinical settings. As I said previously, we expect to have our interim assessment in the first half of 2020. And lastly to a question regarding a potential metrics, we plan to share metrics on the EscharEx study once the uncertainties wavered and we will provide you with more insights of the EscharEx study progress and recruitment base.

Great. And then -- and just thinking about, you historically talked about the second trial with EscharEx I believe in either VLU or DFU based off of the interim analysis and that could potentially start most of your interim analysis data is in hand. Any updated thoughts or strategies on potential second trial? Thanks for taking the questions.

Thank you. So, currently we did not change the strategy. The strategy remains same, means we have the same plan. And as you know, we are data-driven company and based on the data that we will have and the result in the interim, later on in the final results of the study, this will be the data that will we use to discuss with the FDA and discuss within the next step of the development and our plans remains the same.

Excellent. Thank you.

Thank you.

Your next question comes from the line of Kevin DeGeeter with Oppenheimer.

Hey, great. Thanks for taking my questions guys. Can you talk a little bit about changes you may be seeing in response to COVID-19 in practice protocols, specifically have you seen either any survey work or plan to do any survey work yourself to capture whether or not there's a shift away from surgical debridement towards non-surgical methodologies? And how are you thinking about the best way to monitor whether there will, in fact, be a sustained change and burn protocols with regard to debridement cleaning of wound.

Thank you for the question, Kevin. So, generally speaking, as I said before, we know that NexoBrid has been less directly impacted by the pandemic keeping the critical nature of the severe burns. On one hand, we've been discussing with some of the burn centers and we are keeping a close relation with all our customers and our stakeholders also in the U.S. as part of the clinical setting and -- which have been communicating on the fact that with the less industrial activity, less burn patient have been admitted for treatment recently. Having said that, on the other hand, we will encourage from recent guidelines such as the Italian guidelines that recommending to shift more burn patient and treatment from the surgical treatment towards the non-surgical treatment or most specifically to the non-surgical enzymatic care in order to alleviate the burden on acute care staff and inpatient operation room. And we believe this will enhance NexoBrid as a standard of care and underscoring its role as often dramatic debridement for burn care in emergencies.

Great. That's extremely helpful. And then, maybe following up on some of the questions with regard to metrics to think about enrollment of the EscharEx study. I appreciate that. There’s a lot of uncertainty at the moment and perhaps you can frame for us though, what portion of sites that were opened during Q1 are under current local regulations allow to consider reinitiating patient enrollment into the study. Is it 90%, is it 60% of the sites that you open? Because it is a little bit difficult to measure just given how variable and heterogeneous some of these local policies are to understand the impact on a specific study.

[Operator Instructions] Your next question comes from the line of Swayampakula with H.C. Wainwright.

Good afternoon, Sharon and Boaz. I hope you guys are doing well. Most of my questions have been answered. But just want to follow-up a little bit on the NexoBrid delivery to BARDA. Just trying to understand, how confident are you about your delivery timelines considering COVID-19? And also how confident are your BARDA going through the whole procurement, not only for the -- for the $16 million -- initial $16 million, but also the additional agreement that you got into BARDA with? Hello?

And excuse me, this is the operator. I apologize about the interruption. Please pause as one of our speakers has lost a connection. And this is the operator. We do have our speaker back on. You may resume with your question.

Sure. Thank you. Hi, Sharon, Boaz. Good afternoon. Can you guys hear me now?

Yeah. First of all, I apologize to all. And Kevin, I hoped you've helped my response to the question. And if no, I will repeat it. Go ahead RK.

Okay. And then thank you for taking my questions. As I was saying, most of my questions have been answered. But just trying to follow-up on the next NexoBrid delivery to BARDA. How confident are you on delivering the current procurement order? And also, your confidence on BARDA not only linked to this -- the $16 million, but also that additional one that there that you had announced earlier? I'm just trying to get a feel for like how confident both of them are going to happen.

So, we -- I will start with first one, the committed one, which BARDA initiated the procurement earlier this year. So, for that part of the $16.5 million growth, we are fully confident and highly confident. As I said, we began manufacturing of this stock and we stockpile currently the stock and maintain it in Israel until we will be able to deliver it in light of the restriction -- or air restriction or any other friction as a result of the COVID-19. Following those restrictions and due to shifting priorities, BARDA just requested an adjustment to the original delivery plan, which we made. And currently, we are discussing together BARDA and our team. And currently the tentative delivery date for the first delivery is expected in the third quarter, early third quarter, means that we are highly confident that we do expect to recognize revenue in the third quarter and in the fourth quarter going forward to 2021. As to the second part, which is the option of BARDA to increase the procurement by up to additional $50 million, this is subject to BARDA for discussion. And as a reminder, this option can be utilized -- targeted to be utilized either when the initial stock will be expired in order to rotate this expiry stock or to extend or increase the safety stock that BARDA defined originally back in 2015.

Okay. Great. And then, on the EscharEx study in the United States, maybe -- I'm not sure if you answered this question yet. How many centers are open at this point traditions -- randomization. And how is the randomization going at this point?

Okay. So, I will repeat what I started to respond to Kevin before we hung up, and it will provide you the full answer. At the date of the suspension of this study, we've been in a position at about 20 sites overall active after SIVs ready for enrollment. Our plan is to have -- as a reminder about 25 to 30 sites overall, the majority of them in the U.S. Currently fall into discussion with PIs and inputs we get from the site, we assume that activity in regions where restrictions have been lifted and we have about 70%, 75% of the active sites ready and we plan to gradually have all of the -- all the 25 sites in the coming few months subject, of course, to local government policies, evolvement over the coming months.

Okay. Thank you very much. Thanks for taking the questions.

And we do have a follow-up question from the line of Kevin DeGeeter with Oppenheimer.

Great. Just really housekeeping questions for me. Can you provide just some additional metrics as to how to think about within the $8 million to $10 million burn guidance, a range of assessment for potential BARDA procurement contribution or some other metric with regard to the top line contribution? Just to be able to more fully appreciate perhaps the magnitude, somebody's operating expense adjustments you described in the call.

Thanks, Kevin for the question. I will turn the call over to Boaz and he will in response provide you with an answer. Please Boaz.

Hi, Kevin. So, first, we'd like to mention that we feel very comfortable with our liquidity position and the cash we have on hand. And the fact that I have no debt. And NexoBrid is a cash generating product. While there is a shift of revenues from BARDA procurement to 2021 and Sharon indicated we expected the cost saving in the short-term as a result of the EscharEx study suspension and reduction in its associated variable costs. In addition, we've also deferred some of the capital projects in order to reduce the cost utilization. So, overall, I think if we look at the range, in the upper range previously, I think right now, that not only that we maintained the cash operating, but we see a slight improvement in the guidance. But we still want to remain at that range.

Great. Thank you for that.

And there are no further questions at this time.

Thank you everyone for joining us today. We look forward to continuing executing on our strategy and bringing new therapies to market and to updating you again on our next quarterly update call. Thank you and have a great day.

This concludes today's conference call. You may now disconnect.